MedTrace Logo

BMB-101 in Absence Epilepsy and DEE

NCT06401538 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-12

No results posted yet for this study

Summary

The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.

Conditions

  • Absence Epilepsy
  • Jeavons Syndrome
  • Dravet Syndrome
  • Lennox Gastaut Syndrome

Interventions

DRUG

BMB-101

BMB-101 liquid administered orally twice a day for 3 months

Sponsors & Collaborators

  • Bright Minds Biosciences Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Terence O'Brien, MD · The Alfred

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-05
Primary Completion
2025-09-15
Completion
2025-11-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06401538 on ClinicalTrials.gov